A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients

References

• Bray F, Ferlay J, Soerjomataram I,Siegel RL, Torre LA, Jemal A,. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Chen, W. , Zheng R. , Zeng H. , Zhang S. The updated incidences and mortalities of major cancers in China, 2011. Chin J Cancer. 2015;34(11):502–507. doi:10.1186/s40880-015-0042-626370301
   PubMedGoogle Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.2120824399786
   PubMed Web of Science ®Google Scholar
• Zheng R, Zeng H, Zhang S, Chen W. Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):66. doi:10.1186/s40880-017-0234-328818111
   PubMedGoogle Scholar
• Zong L, Abe M, Seto Y, Ji J. The challenge of screening for early gastric cancer in China. Lancet. 2016;388(10060):2606. doi:10.1016/S0140-6736(16)32226-727894662
   PubMed Web of Science ®Google Scholar
• Fang C, Wang W, Deng J-Y, et al. Proposal and validation of a modified staging system to improve the prognosis predictive performance of the 8th AJCC/UICC pTNM staging system for gastric adenocarcinoma: a multicenter study with external validation. Cancer Commun (Lond). 2018;38(1):67. doi:10.1186/s40880-018-0337-530454049
   PubMedGoogle Scholar
• Wang W, Sun Z, Deng J-Y, et al. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. Cancer Commun (Lond). 2018;38(1):23. doi:10.1186/s40880-018-0293-029764518
   PubMedGoogle Scholar
• Fujitani K, Yang H-K, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–318. doi:10.1016/S1470-2045(15)00553-726822397
   PubMed Web of Science ®Google Scholar
• He, M.M. , Zhang D.S. , Wang F. , et al. The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer. PLoS One. 2013;8(12):e83921. doi:10.1371/journal.pone.005976024358318
   PubMed Web of Science ®Google Scholar
• Yuan SQ, Nie R-C, Chen S, et al. Selective gastric cancer patients with peritoneal seeding benefit from gastrectomy after palliative chemotherapy: a propensity score matching analysis. J Cancer. 2017;8(12):2231–2237. doi:10.7150/jca.1893228819425
   PubMed Web of Science ®Google Scholar
• Hsu JT, Liao J-A, Chuang H-C, et al. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer. BMC Palliat Care. 2017;16(1):19. doi:10.1186/s12904-017-0192-128288593
   PubMedGoogle Scholar
• Chang YR, Han DS, Kong S-H, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol. 2012;19(4):1231–1239. doi:10.1245/s10434-011-2056-x22045464
   PubMed Web of Science ®Google Scholar
• Chiu CF, Yang H-R, Yang M-D, et al. Palliative gastrectomy prolongs survival of metastatic gastric cancer patients with normal preoperative CEA or CA19-9 values: a retrospective cohort study. Gastroenterol Res Pract. 2016;2016:1–9. doi:10.1155/2016/6846027
   Web of Science ®Google Scholar
• Dittmar Y, Rauchfuss F, Goetz M, et al. Non-curative gastric resection for patients with stage 4 gastric cancer-a single center experience and current review of literature. Langenbecks Arch Surg. 2012;397(5):745–753. doi:10.1007/s00423-012-0902-322307547
   PubMed Web of Science ®Google Scholar
• Ebinger SM, Warschkow R, Tarantino I, Schmied BM, Güller U, Schiesser M. Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer. 2016;19(3):723–734. doi:10.1007/s10120-015-0541-926391158
   PubMed Web of Science ®Google Scholar
• Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. 2014;34(5):2079–2085. 24778009
   PubMed Web of Science ®Google Scholar
• Schmidt T, Alldinger I, Blank S, et al. Surgery in oesophago-gastric cancer with metastatic disease: treatment, prognosis and preoperative patient selection. Eur J Surg Oncol. 2015;41(10):1340–1347. doi:10.1016/j.ejso.2015.05.00526213358
   PubMed Web of Science ®Google Scholar
• Ho DE, Gary King KI, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8). doi:10.18637/jss.v042.i08
   Web of Science ®Google Scholar
• Hsu JT, Liao J-A, Chuang H-C, et al. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer. BMC Palliat Care. 2017;16:9. doi:10.1186/s12904-017-0192-128118824
   PubMed Web of Science ®Google Scholar
• Warschkow R, Baechtold M, Leung K, et al. Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population. Gastric Cancer. 2018;21(2):324–337. doi:10.1007/s10120-017-0742-528646258
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang W-K, Shin D-B, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–673. doi:10.1093/annonc/mdn71719153121
   PubMed Web of Science ®Google Scholar
• Luo HY, Xu R-H, Wang F, et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy. 2010;56(2):94–100. doi:10.1159/00030525620357440
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–221. doi:10.1016/S1470-2045(08)70035-418282805
   PubMed Web of Science ®Google Scholar
• Dai X, Zhang X, Wang C, Jiang J, Wu C. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients. Oncotarget. 2017;8(18):30495–30501. doi:10.18632/oncotarget.1372127911869
   PubMedGoogle Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–4997. doi:10.1200/JCO.2006.06.842917075117
   PubMed Web of Science ®Google Scholar
• Wang J, Xu R, Li J, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016;19(1):234–244. doi:10.1007/s10120-015-0457-425604851
   PubMed Web of Science ®Google Scholar
• Nomura E, Lee S-W, Tokuhara T, Nitta T, Kawai M, Uchiyama K. Functional outcomes according to the size of the gastric remnant and the type of reconstruction following distal gastrectomy for gastric cancer: an investigation including total gastrectomy. Jpn J Clin Oncol. 2013;43(12):1195–1202. doi:10.1093/jjco/hyt14124065202
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa05553116822992
   PubMed Web of Science ®Google Scholar